@article{HefnerBerberichLanversetal.2017, author = {Hefner, Jochen and Berberich, Sara and Lanvers, Elena and Sanning, Maria and Steimer, Ann-Kathrin and Kunzmann, Volker}, title = {New insights into frequency and contents of fear of cancer progression/recurrence (FOP/FCR) in outpatients with colorectal carcinoma (CRC) receiving oral capecitabine: a pilot study at a comprehensive cancer center}, series = {Patient Preference and Adherence}, volume = {11}, journal = {Patient Preference and Adherence}, doi = {10.2147/PPA.S142784}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-158476}, pages = {1907-1914}, year = {2017}, abstract = {Background: Fear of cancer progression/recurrence (FOP/FCR) is considered one of the most prevalent sources of distress in cancer survivors and associated with lower quality of life and functional impairment. Detailed measures of FOP/FCR are needed because little is known about the knowledge of FOP/FCR, its associations with the patient-doctor relationship, and the rate of adequate therapy. Colorectal cancer (CRC) is one of the most prevalent cancer entities, and oral capecitabine is widely prescribed as treatment. Therefore, we initiated a pilot study to expand the literature on FOP/FCR in CRC outpatients receiving capecitabine and to generate hypotheses for future investigations. Methods: This study included 58 patients treated at a comprehensive cancer center. FOP/FCR was assessed with the Fear of Progression Questionnaire (FOP-Q-SF). Satisfaction with the relationships with doctors was assessed with the Patient-Doctor Relationship Questionnaire-9 (PRDQ-9). Levels of side effects were rated by the patients on a visual analog scale. Clinical data were extracted from the charts. Results: A total of 19 out of 58 patients (36\%) suffered from FOP/FCR according to our assessment. Levels of FOP/FCR seemed to be mostly moderate to high. Only four out of the 19 distressed patients (21\%) were treated accordingly. Typical side effects of oncological treatment were associated with higher FOP/FCR. Satisfaction with doctor-patient relationships was not associated with FOP/FCR. Regarding single items of FOP/FCR, three out of the five most prevalent fears were associated with close relatives. Discussion: FOP/FCR occurred frequently in more than one in three patients, but was mostly untreated in this sample of consecutive outpatients with CRC receiving oral capecitabine. In detail, most fears were related to family and friends. In addition to an unmet need of patients, our data indicate sources of distress not considered thus far. If replicated in larger studies, results may help to inform intervention development and improve patient care.}, language = {en} } @article{HefnerBerberichLanversetal.2018, author = {Hefner, Jochen and Berberich, Sara and Lanvers, Elena and Sanning, Maria and Steimer, Ann-Kathrin and Kunzmann, Volker}, title = {Patient-doctor relationship and adherence to capecitabine in outpatients of a German comprehensive cancer center}, series = {Patient Preference and Adherence}, volume = {12}, journal = {Patient Preference and Adherence}, doi = {10.2147/PPA.S169354}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-177143}, pages = {1875—1887}, year = {2018}, abstract = {Purpose: The prescribing of oral chemotherapy agents has introduced the new challenge of ensuring patients' adherence to therapy. Aspects of a close patient-doctor relationship are reported to be correlated with adherence to oral anticancer drugs, but data on capecitabine are scarce. Patients and methods: Sixty-four outpatients with a diagnosis of cancer and prescribed capecitabine were recruited from a German Comprehensive Cancer Center. We used the Patient-Doctor Relationship Questionnaire (PDRQ-9), the Medical Adherence Rating Scale (MARS), the Beliefs about Medicines Questionnaire (BMQ), and the Satisfaction with Information about Medicines Scale (SIMS) to assess patients' perceptions and behavior. Medical data were extracted from the charts. Results: Non-adherence was reported by 20\% of the 64 participants. The perceived quality of the patient-doctor relationship was high in general, but it did not emerge as a predictor of adherence in our survey (odds ratio [OR]=0.915, P=0.162, 95\% CI=0.808-1.036). However, beliefs about medicine (OR=1.268, P<0.002; 95\% CI=1.090-1.475) as well as satisfaction with information about medicine (OR=1.252, P<0.040, 95\% CI=1.010-1.551) were predictors of adherence and the quality of the patient-doctor relationship was correlated with both variables (r=0.373, P=0.002 for SIMS sum score; r=0.263, P=0.036 for BMQ necessity/concern difference). Overall, adherence to capecitabine was high with a conviction that the therapy is necessary. However, concerns were expressed regarding the long-term effect of capecitabine use. Patients have unmet information needs regarding interactions of capecitabine with other medicines and the impairment of their intimate life. Conclusions: In order to ensure adherence to capecitabine, our results seem to encourage the default use of modern and perhaps more impersonal means of information brokerage (eg, email, internet). However, the contents of some of patients' informational needs as well as the associations of patients' beliefs and satisfaction about the information received suggest a benefit from a trustful patient-doctor relationship.}, language = {en} } @phdthesis{Steimer2021, author = {Steimer, Ann-Kathrin}, title = {Adh{\"a}renz bei oraler Capecitabin-Therapie - Zusammenh{\"a}nge mit Angstst{\"o}rungen}, doi = {10.25972/OPUS-24964}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-249647}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2021}, abstract = {Laut Sch{\"a}tzungen des Robert Koch-Instituts erkranken j{\"a}hrlich fast 500.000 Personen an einer Krebserkrankung, mit steigender Tendenz. Durch stetige Fortschritte in der Forschung kam es durch die Entwicklung einer Chemotherapie in Tablettenform zu einem Paradigmenwechsel in der Krebstherapie. F{\"u}r ein optimales Therapie-Outcome ist es von großer Bedeutung, dass die Patienten ein adh{\"a}rentes Verhalten zeigen. Weiterhin zeigt sich in der bisherigen Literatur, dass psychische Komorbidit{\"a}ten die Adh{\"a}renz und damit den Behandlungserfolg gleichermaßen beeinflussen k{\"o}nnen. Dies wurde in der vorliegenden Arbeit evaluiert. Die Studie umfasste insgesamt 69 Krebspatientinnen und -Patienten, die eine Chemotherapie mit Capecitabin erhielten. Untersucht wurden Gruppenunterschiede zwischen soziodemografischen und klinischen Variablen auf der einen Seite und Adh{\"a}renz auf der anderen Seite sowie die klinisch relevante Belastung durch Angstsymptome. Zur Datenerhebung wurden zum einen der MARS-Fragebogen zur Erfassung der Adh{\"a}renz und zum anderen der GAD-7 zur Erfassung der Angstsymptomatik verwendet. Adh{\"a}rentes Verhalten in Bezug auf die Einnahme von Capecitabin zeigte sich bei 75.4\% der Personen im untersuchten Studienkollektiv. Dieses Ergebnis steht in Einklang mit bisherigen Publikationen, die ebenfalls den Zusammenhang zwischen Adh{\"a}renz bei Capecitabin untersuchten. Die weitere Hypothese war, dass h{\"o}here Angstbelastungen unter Patienten signifikant mit einer verminderten Adh{\"a}renz in Zusammenhang stehen. Dies konnte in der vorliegenden Studie jedoch nicht festgestellt werden. Einerseits zeigte zwar nur ein geringer Anteil der untersuchten Patienten Hinweise einer Angstst{\"o}rung (7\%), andererseits wurde festgestellt, dass nicht alle dieser Patienten eine psychotherapeutische Behandlung erhielten. F{\"u}r zuk{\"u}nftige Forschungen w{\"a}re zu {\"u}berlegen, weitere Messinstrumente zur Diagnostik einer niederschwelligen Angst einzusetzen. Weiterhin w{\"a}ren ein gr{\"o}ßeres Therapieangebot und umfassendere psychosoziale Unterst{\"u}tzung dringend erforderlich. Abschließend bleibt festzuhalten, dass in Zukunft weitere Studien, v.a. auch mit gr{\"o}ßeren Fallzahlen sowie L{\"a}ngsschnitt- oder Follow-up-Studien zu diesem Forschungsthema dringend indiziert sind.}, subject = {Capecitabin}, language = {de} }